Health Technology Assessment
Rigorous evaluation of health interventions — including AI-enabled and emerging technologies — informing coverage, reimbursement, and regulatory decisions.
Independent Research at the Frontier of Health Technology
Advancing the evidence base for health technology assessment in an era of rapid innovation.
ExploreAuridici is an independent research company working at the intersection of health technology assessment, outcomes measurement, and real-world evidence generation — with a particular focus on evaluating cutting-edge and AI-enabled technologies as they enter clinical and everyday use.
We are not advisers and we are not theorists. We conduct rigorous, mixed-methods research designed to inform regulatory, coverage, and investment decisions. Where the evidence demands it, our work challenges established methodology rather than deferring to it.
Our foundation is built on health economics, bioethics, psychometrics, and applied data science. We are international in scope and rooted in Ireland — generating evidence that holds up to scrutiny wherever decisions are made.
Rigorous evaluation of health interventions — including AI-enabled and emerging technologies — informing coverage, reimbursement, and regulatory decisions.
Development and validation of patient-reported outcome instruments, psychometric analysis, and quality-of-life measurement in complex and progressive conditions.
Mixed-methods research spanning qualitative and quantitative approaches, multinational studies, and evidence generation beyond the clinical trial.
Advancing HTA methods for populations and technologies where standard approaches fall short — adaptive, person-centred, and ethics-grounded by design.
“Evidence that holds — across populations, across technologies, across borders.”
Free from commercial and institutional agendas. Our conclusions follow the evidence, not the client.
Qualitative depth meets quantitative rigour — grounded in lived experience and powered by data.
We build methods for the places standard approaches fall short, guided throughout by ethics.
We welcome enquiries from institutional partners, investors, and regulatory bodies.